Stephen Bruce Baylin - Cancer Science

Author Information

Stephen Bruce Baylin is a distinguished researcher affiliated with the Department of Oncology and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine in Baltimore, Maryland, USA. His extensive work in the field of oncology, particularly focusing on cancer research, has contributed significantly to advancing our understanding of cancer mechanisms and treatment strategies.

Research Contributions

Stephen Baylin has made substantial contributions to cancer research, with a particular interest in epigenetics and the molecular basis of cancer. His recent work includes investigating the molecular interactions during SARS-CoV-2 infection, as well as exploring innovative therapies for acute myeloid leukemia and colorectal cancer. Notably, his research often delves into the interplay between cancer-driving mutations and the immune response, aiming to develop more effective therapeutic interventions.

Aliases

Stephen Bruce Baylin is known by several aliases within the academic community, including S B Baylin, Steven Baylin, Stephen B Baylin, and Steve B Baylin. These variations are used interchangeably across different publications and databases.

Publication and Citation Metrics

Metric	Value
Total Papers Published	638
Total Citation Count	188,195
h-index	170

Publications:

TARGETED DOWN REGULATION OF CORE MITOCHONDRIAL GENES DURING SARS-COV-2 INFECTION

DOI: 10.1101/2022.02.19.481089

Year: 2022

The interplay between lncRNAs, RNA-binding proteins and viral genome during SARS-CoV-2 infection reveals strong connections with regulatory events involved in RNA metabolism and immune response

DOI: 10.1101/2022.03.26.485903

Year: 2022

Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed/refractory acute myeloid leukemia.

DOI: 10.1158/1078-0432.CCR-21-3729

Year: 2022

Clinical Significance of Plasma CD9-Positive Exosomes in HIV Seronegative and Seropositive Lung Cancer Patients

DOI: 10.3390/cancers13205193

Year: 2021

Abstract CT121: A Phase II trial of guadecitabine (G) plus atezolizumab (A) in patients with metastatic urothelial carcinoma (UC) progressing after initial checkpoint inhibitor therapy

DOI: 10.1158/1538-7445.AM2021-CT121

Year: 2021

Bacterial-driven inflammation and mutant BRAF expression combine to promote murine colon tumorigenesis that is sensitive to immune checkpoint therapy.

DOI: 10.1158/2159-8290.CD-20-0770

Year: 2021

Abstract 2107: Transcription factor repertoire basis for epigenetic and consensus molecular subtypes of colorectal cancer

DOI: 10.1158/1538-7445.AM2021-2107

Year: 2021

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

DOI: 10.1038/s43018-021-00249-x

Year: 2021

The Great Deceiver: miR-2392’s Hidden Role in Driving SARS-CoV-2 Infection

DOI: 10.1101/2021.04.23.441024

Year: 2021

Role of miR-2392 in driving SARS-CoV-2 infection

DOI: 10.1016/j.celrep.2021.109839

Year: 2021

What is the significance of biomarkers in cancer therapy?

How Can Family Members Benefit from Psychological Support?

What Are the Symptoms of Burnout?

How Does Genomics Apply to Cancer?

Are There Any Limitations to Targeted Therapy?

What Role Does the FCC Play in Public Health Communications?

How Do High R&D Costs Impact Drug Pricing?

How Do They Conduct Research?

Are There Any New Developments in Vinorelbine Research?

What Role Do Nutrition and Hydration Play in Oral and Overall Health?

Partnered Content Networks

Relevant Topics